Serum Monocyte Chemotactic Protein-1 Levels in Congenital Diaphragmatic Hernia

Overview

Journal Pediatr Surg Int

Specialties General Surgery
Pediatrics

Date 2007 Jan 9

PMID 17206432

Citations 9

Authors

Manabu Okawada

Hiroyuki Kobayashi

Eri Tei

Tadaharu Okazaki

Geoffrey J Lane

Atsuyuki Yamataka

Affiliations

Soon will be listed here.

Abstract

To measure serum monocyte chemotactic protein-1 (MCP-1) in patients with congenital diaphragmatic hernia (CDH) and investigate its relationship to the development of persistent pulmonary hypertension (PPH). Serum MCP-1 was measured in 13 neonates with high risk for CDH at the time of diagnosis and postoperatively, and in five age-matched controls using an ELISA system. The 13 CDH subjects were divided into four groups according to the presence of PPH and outcome. Group I (severe-pre group): subjects with severe PPH who died prior to surgery (n = 5); Group II (mild-pre group): subjects with mild PPH controlled by medications (n = 8); Group IIa (severe-post group): subjects who subsequently developed severe PPH postoperatively and died (n = 3); and Group IIb (mild-post group): subjects who continued to have mild PPH controlled by medications. We also examined nitrofen-induced hypoplastic lungs from five rat fetuses with CDH and five control lung specimens for MCP-1 using immunohistochemistry. Mean serum MCP-1 in Group I was (1038.0 +/- 95.8 pg/ml), which was significantly higher than Group II (444.9 +/- 39.7 pg/ml) (P < 0.0001) and controls (147.3 +/- 11.3 pg/ml) (P < 0.0001). Postoperatively, Group IIa was significantly higher than Group IIb from 24 to 120 h postoperatively (P < 0.001). In Group IIb serum MCP-1 did not rise at all between 24 and 120 h postoperatively. Hypoplastic fetal rat CDH lungs had strong expression of MCP-1 compared with control lungs. Up-regulated expression and high circulating levels of MCP-1 in CDH patients with PPH suggest that MCP-1 may play a role in the development of PPH in CDH.

Citing Articles

Sex-specific differences in the severity of pulmonary hypoplasia in experimental congenital diaphragmatic hernia and implications for extracellular vesicle-based therapy.

Doktor F, Lo E, Fortuna V, Khalaj K, Garcia M, Figueira R Pediatr Surg Int. 2024; 40(1):278.

PMID: 39467854 DOI: 10.1007/s00383-024-05856-0.

Fetal hypoplastic lungs have multilineage inflammation that is reversed by amniotic fluid stem cell extracellular vesicle treatment.

Antounians L, Figueira R, Kukreja B, Litvack M, Zani-Ruttenstock E, Khalaj K Sci Adv. 2024; 10(30):eadn5405.

PMID: 39058789 PMC: 11277482. DOI: 10.1126/sciadv.adn5405.

Anti-inflammatory effects of antenatal administration of stem cell derived extracellular vesicles in the brain of rat fetuses with congenital diaphragmatic hernia.

Blundell M, Doktor F, Figueira R, Khalaj K, Biouss G, Antounians L Pediatr Surg Int. 2023; 39(1):291.

PMID: 37955723 DOI: 10.1007/s00383-023-05578-9.

Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models.

Marulanda K, Tsihlis N, E McLean S, Kibbe M Pediatr Res. 2020; 89(7):1641-1649.

PMID: 33038872 PMC: 8035353. DOI: 10.1038/s41390-020-01191-x.

Prenatal treatment with rosiglitazone attenuates vascular remodeling and pulmonary monocyte influx in experimental congenital diaphragmatic hernia.

Gosemann J, Friedmacher F, Hofmann A, Zimmer J, Kuebler J, Rittinghausen S PLoS One. 2018; 13(11):e0206975.

PMID: 30418988 PMC: 6231640. DOI: 10.1371/journal.pone.0206975.

References

Dorfmuller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G . Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165(4):534-9. DOI: 10.1164/ajrccm.165.4.2012112. View

Tuder R, Voelkel N . Pulmonary hypertension and inflammation. J Lab Clin Med. 1998; 132(1):16-24. DOI: 10.1016/s0022-2143(98)90020-8. View

Kobayashi H, Yamataka A, Okazaki T, Lane G, Puri P, Miyano T . Increased levels of circulating adhesion molecules in neonates with congenital diaphragmatic hernia complicated by persistent pulmonary hypertension. Pediatr Surg Int. 2003; 20(1):19-23. DOI: 10.1007/s00383-003-1072-8. View

Porreca E, di Febbo C, Reale M, Castellani M, Baccante G, Barbacane R . Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. J Vasc Res. 1997; 34(1):58-65. DOI: 10.1159/000159202. View

Katsushi H, Kazufumi N, Hideki F, Katsumasa M, Hiroshi M, Kengo K . Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J. 2004; 68(3):227-31. DOI: 10.1253/circj.68.227. View

Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y . Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2001; 164(2):319-24. DOI: 10.1164/ajrccm.164.2.2006154. View

Molenaar J, Bos A, Hazebroek F, Tibboel D . Congenital diaphragmatic hernia, what defect?. J Pediatr Surg. 1991; 26(3):248-54. DOI: 10.1016/0022-3468(91)90497-h. View

Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L . Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995; 151(5):1628-31. DOI: 10.1164/ajrccm.151.5.7735624. View

Denger S, Jahn L, Wende P, Watson L, Gerber S, Kubler W . Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: induction of the synthetic phenotype: a possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis. 1999; 144(1):15-23. DOI: 10.1016/s0021-9150(99)00033-7. View

10.

Luster A . Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338(7):436-45. DOI: 10.1056/NEJM199802123380706. View

11.

Damas J, Otterdal K, Yndestad A, Aass H, Solum N, Froland S . Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation. 2004; 110(8):999-1005. DOI: 10.1161/01.CIR.0000139859.68513.FC. View

12.

Rollins B . Chemokines. Blood. 1997; 90(3):909-28. View

13.

Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M . Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest. 1998; 114(1 Suppl):50S-51S. DOI: 10.1378/chest.114.1_supplement.50s. View

14.

Colvin J, Bower C, Dickinson J, Sokol J . Outcomes of congenital diaphragmatic hernia: a population-based study in Western Australia. Pediatrics. 2005; 116(3):e356-63. DOI: 10.1542/peds.2004-2845. View

15.

Wilcox D, Irish M, Holm B, Glick P . Pulmonary parenchymal abnormalities in congenital diaphragmatic hernia. Clin Perinatol. 1996; 23(4):771-9. View

16.

Geggel R, Murphy J, Langleben D, Crone R, Vacanti J, Reid L . Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair. J Pediatr. 1985; 107(3):457-64. DOI: 10.1016/s0022-3476(85)80534-5. View

17.

Rollins B, Yoshimura T, Leonard E, Pober J . Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol. 1990; 136(6):1229-33. PMC: 1877579. View

18.

Sica A, Wang J, Colotta F, Dejana E, Mantovani A, Oppenheim J . Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol. 1990; 144(8):3034-8. View

19.

Veyssier-Belot C, Cacoub P . Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res. 2000; 44(2):274-82. DOI: 10.1016/s0008-6363(99)00230-8. View